MAIA Biotechnology Inc

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer.

MAIA Biotechnology Reveals New Data Showing THIO's Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients.

MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas.

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of NSCLC.

MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Repurchase Program.

MAIA Biotechnology Announces Share Repurchase Program

After losing some value lately, a hammer chart pattern has been formed for MAIA Biotechnology, Inc. (MAIA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

MAIA Biotechnology, Inc. (MAIA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--Of the first 11 patients with post-baseline scans, 9 met the disease control primary endpoint at first response assessment.

MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--First 2 patients dosed with THIO continue to be without documented progression for 12.2 and 11.5 months.

MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer

MAIA's THIO-101 trial of 6-thio-2-deoxyguanosine in non-small cell lung cancer had enrolled 29 patients as of a June 20 update from the company. The first two patients in the trial have achieved continued survival at 10 and 11 months following the start of treatment. MAIA has enough cash to make it to an update from the trial, but another cash raise could be ahead.

MAIA Biotechnology: Progress In The THIO-101 Trial Sets Up A 2023 Catalyst

Acrivon Therapeutics Inc

AMTD Digital

Kenvue

Loop Media Inc

Mobileye Global Inc

Warby Parker

In arguably most cases involving expert financial advice, you will encounter guidance toward established enterprises, not up-and-coming stocks to buy. While the latter category certainly dials up the heat in terms of overall sexiness, some folks just can't handle adventurous portfolios.

7 Up-and-Coming Stocks to Buy for the Next Decade

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 has enrolled 29 patients.

MAIA Biotechnology Announces Updates in Enrollment in Phase II Clinical Trial: THIO-101 Has Enrolled 29 Patients

CHICAGO--(BUSINESS WIRE)--Filed provisional new composition of matter patent application for MAIA's third entirely home-grown telomere-targeting molecule.

MAIA Biotechnology Files Second Patent For New Telomere-Targeting Molecules Program

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update. “We are thrilled with the advancement of the THIO-101 trial, inclusive of reporting the positive topline data and preliminary survival data from the completed Part A safety lead-in of our ongoing pha.

MAIA Biotechnology Reports First Quarter 2023 Financial Results and Provides Corporate Update

NEW YORK--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the closing of its previously announced public offering of 2,555,500 shares of its common stock at a public offering price of $2.25 per share, for gross proceeds of approximately $5.75 million, before deducting underwriting discounts and offering expenses. The shares sold in the offering include the exercise in full.

MAIA Biotechnology, Inc. Announces Closing of Public Offering

NEW YORK--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the pricing of an underwritten public offering of 2,222,200 shares of its common stock at a public offering price of $2.25 per share, for gross proceeds of approximately $5 million, before deducting underwriting discounts and other offering expenses. In addition, MAIA has granted the underwriters a.

MAIA Biotechnology, Inc. Announces Pricing of Public Offering

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced preliminary survival data in the Part A safety lead-in of its ongoing phase 2 trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The first 2 patients enrolled in Part A of the study continue to be alive, approximately 10 and 9 months respectively, from treatment initiation.

MAIA Biotechnology Reports Preliminary Survival Data in Part A of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced the peer-reviewed publication of original research article in this month's issue of Molecular Cancer Therapeutics (volume 22, issue 4), a renowned American Association of Cancer Research (AACR) journal that publishes translational research studies focused on the discovery and preclinical development of therapeutic agents for oncology.

MAIA Biotechnology Announces Excellent Efficacy of THIO in Liver Cancer Models

MAIA Biotechnology (MAIA) gains on encouraging data on lead candidate from Part A of its mid-stage study in advanced non-small cell lung cancer.

MAIA Biotechnology (MAIA) Up on Positive Data From NSCLC Study

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced that it will present a poster that will feature the design of its ongoing Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). The poster will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, which is taking place in-person at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.

MAIA Biotechnology to Present at AACR Annual Meeting 2023

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) today announced positive topline data from the completed Part A safety lead-in of the Company's THIO-101 Phase 2 go-to-market trial in advanced Non-Small Cell Lung Cancer (NSCLC) and has commenced recruitment in Part B randomized efficacy/dose selection.

MAIA Biotechnology Reports Positive Topline Data from Part A Safety Lead-In of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today reported financial results for the full year ended December 31, 2022, and provided a corporate update.

MAIA Biotechnology Reports Full Year 2022 Financial Results and Provides Corporate Update

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today the Company has no exposure to Silicon Valley Bank (“SVB”). The Company is aware that the Federal Deposit Insurance Corp. has taken control of SVB due to liquidity concerns. The Company confirms it does not hold any deposits or investments at SVB, as well as at Silvergate Bank, or Signature Bank. MAIA's cash is managed across a top-tier financial institution. About MAIA Biotechnology, Inc.

MAIA Biotechnology Announces No Exposure to Silicon Valley Bank

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today that the first two patients have been dosed in Europe in MAIA's Phase 2 clinical trial, THIO-101 evaluating THIO in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Following regulatory clearances in Hungary, Poland, and Bulgaria, five clinical sites have been activated in these three European countries.

MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today it intends to initiate its second Phase 2 go-to-market trial evaluating THIO, the world's first telomere-targeting agent, in patients with four cancer indications. The FDA has awarded MAIA's lead anti-cancer agent THIO two Orphan Drug Designations, based on the preclinical efficacy data, for liver (hepatocellular carcinoma) and small cell lung cancer models.

ADDING MULTIMEDIA: MAIA Biotechnology's Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition

News for MAIA Biotechnology Inc Stock (MAIA)